Paula Hensley, MD
Psychiatry · Albuquerque, NMNPI 1811903487
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,141 of the $1,340 with a category attached, or 85.1%. 10 manufacturers reported payments, led by Alkermes, Inc. at 34.7% of the total.
Across 20 payments — averaging $67.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$465
- H2-pharma, LLC$150
- Otsuka Pharmaceutical Development & Commercialization, Inc.$137
- Johnson & Johnson$115
- Neurocrine Biosciences, Inc.$112
- Teva Pharmaceuticals USA, Inc.$111
- plus $251 from 4 others
Across 80 payments — averaging $292.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$23K
What the payments were for
- Speaking & faculty fees$15011%
- Food & beverage$1,14185%
- Education$494%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 5 | $465 |
| H2-pharma, LLC | 1 | $150 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $137 |
| Johnson & Johnson | 1 | $115 |
| Neurocrine Biosciences, Inc. | 1 | $112 |
| Teva Pharmaceuticals USA, Inc. | 2 | $111 |
| Acadia Pharmaceuticals Inc | 1 | $104 |
| Otsuka America Pharmaceutical, Inc. | 1 | $50 |
| Eisai Inc. | 1 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,340 in reported general payments places this provider in the 85th percentile of 174 psychiatry providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 26 | $50,705 |
| Lurasidone Hcl | 12 | $5,262 |
| Prazosin Hcl | 31 | $1,748 |
| Atomoxetine Hcl | 15 | $1,729 |
| Bupropion XlBupropion Hcl | 33 | $937 |
| Clozapine | 15 | $748 |
| Gabapentin | 31 | $575 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 30 | $564 |
| Clonazepam | 63 | $468 |
| Lorazepam | 52 | $451 |
| Trazodone Hcl | 30 | $451 |
| Mirtazapine | 24 | $389 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $378 |
| Citalopram HbrCitalopram Hydrobromide | 15 | $165 |
| Quetiapine Fumarate | 16 | $139 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Albuquerque
- Patricio EscalonaAlbuquerque$487K
- Mauricio TohenAlbuquerque$160K
- Shiva SharmaAlbuquerque$140K
- Javier VeraAlbuquerque$8K
- Nancy MartinAlbuquerque$6K
- Reuben SutterAlbuquerque$5K
- Swala AbramsAlbuquerque$3K
- David EarlAlbuquerque$3K
- Ronald RomanikAlbuquerque$2K
- Anthony HolzgangAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.